Business Description
PolyPeptide Group AG
Dammstrasse 19, Zug, CHE, 6300
Compare
Compare
Traded in other countries / regions
PPGN.Switzerland
Description
PolyPeptide Group AG is a contract development and manufacturing organization. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.57 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | 0.21 | |||||
| Interest Coverage | 22.76 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 6.35 | |||||
| Beneish M-Score | -2.42 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.6 | |||||
| 3-Year EBITDA Growth Rate | 14.4 | |||||
| 3-Year EPS without NRI Growth Rate | 19.5 | |||||
| 3-Year Book Growth Rate | 33.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 8.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.59 | |||||
| 9-Day RSI | 34.3 | |||||
| 14-Day RSI | 33.52 | |||||
| 6-1 Month Momentum % | -42.89 | |||||
| 12-1 Month Momentum % | -52.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.19 | |||||
| Quick Ratio | 2.1 | |||||
| Cash Ratio | 1.31 | |||||
| Days Inventory | 209.1 | |||||
| Days Sales Outstanding | 71.01 | |||||
| Days Payable | 46.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.71 | |||||
| Forward Dividend Yield % | 0.71 | |||||
| 5-Year Yield-on-Cost % | 0.71 | |||||
| 3-Year Average Share Buyback Ratio | -3.3 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 35.35 | |||||
| Operating Margin % | 22.74 | |||||
| Net Margin % | 16.79 | |||||
| ROE % | 14.4 | |||||
| ROA % | 9.17 | |||||
| ROIC % | 13.73 | |||||
| ROC (Joel Greenblatt) % | 22.7 | |||||
| ROCE % | 15.43 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 26.72 | |||||
| Forward PE Ratio | 36.9 | |||||
| PE Ratio without NRI | 26.72 | |||||
| PS Ratio | 4.47 | |||||
| PB Ratio | 3.17 | |||||
| Price-to-Tangible-Book | 3.28 | |||||
| Price-to-Operating-Cash-Flow | 21.08 | |||||
| EV-to-EBIT | 19.09 | |||||
| EV-to-Forward-EBIT | 27.2 | |||||
| EV-to-EBITDA | 14.36 | |||||
| EV-to-Forward-EBITDA | 17.56 | |||||
| EV-to-Revenue | 4.24 | |||||
| EV-to-Forward-Revenue | 4.33 | |||||
| EV-to-FCF | -61.1 | |||||
| Price-to-Graham-Number | 1.97 | |||||
| Price-to-Net-Current-Asset-Value | 8.47 | |||||
| Earnings Yield (Greenblatt) % | 5.24 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 300.772 | ||
| EPS (TTM) (CHF) | 1.572 | ||
| Beta | 0 | ||
| Volatility % | 66.66 | ||
| 14-Day RSI | 33.52 | ||
| 14-Day ATR (CHF) | 2.511117 | ||
| 20-Day SMA (CHF) | 44.468 | ||
| 12-1 Month Momentum % | -52.78 | ||
| 52-Week Range (CHF) | 38.02 - 147.4 | ||
| Shares Outstanding (Mil) | 33.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PolyPeptide Group AG Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||